Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696696 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00696696 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 45 participants.
The verdict
NCT00696696, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Sorafenib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696696
The ClinicalTrials.gov registry entry for NCT00696696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00696696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696696 about?
NCT00696696 is a clinical study titled "Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer". This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
What is the current status of trial NCT00696696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2007-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00696696?
The interventions under investigation include: Gemcitabine (DRUG), Sorafenib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00696696?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.